Intellia Logo.png

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine.

Contact email: Marissa.igo@intelliatx.com.

Intellia Digital FactSheet

banner_564x405 (003).jpg
Intellia Therapeutics_Image 1
Intellia Therapeutics_Image 1

Describe your image

press to zoom
Intellia Therapeutics_Image 2
Intellia Therapeutics_Image 2

press to zoom
Intellia Therapeutics_Image 3
Intellia Therapeutics_Image 3

press to zoom
Intellia Therapeutics_Image 1
Intellia Therapeutics_Image 1

Describe your image

press to zoom
1/3
Nous contacter

Merci pour votre envoi !